At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; Roche
- Class Antivirals; Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 19 Sep 2001 No-Development-Reported for Influenza virus infections in USA (Unknown route)
- 02 Sep 1998 New profile
- 02 Sep 1998 Preclinical development for Influenza virus infections in USA (Unknown route)